Log in

Cellectar Biosciences News Headlines (NASDAQ:CLRB)

$2.93
+0.04 (+1.38 %)
(As of 02/18/2020 04:26 AM ET)
Today's Range
$2.68
Now: $2.93
$3.04
50-Day Range
$2.17
MA: $2.59
$2.93
52-Week Range
$1.04
Now: $2.93
$3.75
Volume386,596 shs
Average Volume150,152 shs
Market Capitalization$27.54 million
P/E RatioN/A
Dividend YieldN/A
Beta1.34

Headlines

Cellectar Biosciences (NASDAQ CLRB) News Headlines

Source:
DateHeadline
 Brokerages Expect Cellectar Biosciences Inc (NASDAQ:CLRB) to Post -$0.36 EPS Brokerages Expect Cellectar Biosciences Inc (NASDAQ:CLRB) to Post -$0.36 EPS
www.americanbankingnews.com - February 12 at 2:20 AM
Cellectar Biosciences Inc (NASDAQ:CLRB) Sees Large Growth in Short InterestCellectar Biosciences Inc (NASDAQ:CLRB) Sees Large Growth in Short Interest
www.americanbankingnews.com - February 11 at 9:51 PM
Cellectar Biosciences Inc (NASDAQ:CLRB) Sees Significant Decline in Short InterestCellectar Biosciences Inc (NASDAQ:CLRB) Sees Significant Decline in Short Interest
www.americanbankingnews.com - January 26 at 10:16 PM
Should You Be Concerned About Cellectar Biosciences, Inc.'s (NASDAQ:CLRB) Historical Volatility?Should You Be Concerned About Cellectar Biosciences, Inc.'s (NASDAQ:CLRB) Historical Volatility?
finance.yahoo.com - January 17 at 9:53 AM
Cellectar Biosciences (CLRB) Presents At Biotech Showcase 2020 - SlideshowCellectar Biosciences (CLRB) Presents At Biotech Showcase 2020 - Slideshow
seekingalpha.com - January 14 at 10:08 PM
Cellectar Biosciences to Host a CLR 131 Clinical Data Call with Its Phase 2 Lead Investigator on February 19, 2020Cellectar Biosciences to Host a CLR 131 Clinical Data Call with Its Phase 2 Lead Investigator on February 19, 2020
finance.yahoo.com - January 9 at 2:28 PM
Cellectar Appoints Dr. Igor Grachev as Chief Medical OfficerCellectar Appoints Dr. Igor Grachev as Chief Medical Officer
finance.yahoo.com - January 7 at 5:53 PM
Cellectar Bio up 11% premarket on Orphan Drug tag for CLR 131 in LPLCellectar Bio up 11% premarket on Orphan Drug tag for CLR 131 in LPL
seekingalpha.com - January 6 at 4:31 PM
Cellectar Receives Orphan Drug Designation for CLR 131 in Lymphoplasmacytic Lymphoma (LPL)Cellectar Receives Orphan Drug Designation for CLR 131 in Lymphoplasmacytic Lymphoma (LPL)
finance.yahoo.com - January 6 at 4:31 PM
Cellectar Biosciences to Present at Biotech Showcase 2020Cellectar Biosciences to Present at Biotech Showcase 2020
finance.yahoo.com - December 19 at 12:23 PM
BRIEF-Cellectar Announces Data From 20 Patients Receiving Single 25mCi/M2 Bolus Dose Of CLR 131 In Phase 2 CLOVER-1 StudyBRIEF-Cellectar Announces Data From 20 Patients Receiving Single 25mCi/M2 Bolus Dose Of CLR 131 In Phase 2 CLOVER-1 Study
www.msn.com - December 16 at 7:05 PM
Cellectar Announces Data From 20 Patients Receiving a Single 25mCi/M2 Bolus Dose of CLR 131 in the Phase 2 CLOVER-1 StudyCellectar Announces Data From 20 Patients Receiving a Single 25mCi/M2 Bolus Dose of CLR 131 in the Phase 2 CLOVER-1 Study
finance.yahoo.com - December 16 at 9:04 AM
Cellectar Presents Poster at the American Association for Cancer Research (AACR) San Antonio Breast Cancer SymposiumCellectar Presents Poster at the American Association for Cancer Research (AACR) San Antonio Breast Cancer Symposium
finance.yahoo.com - December 13 at 12:25 PM
Fractionated Dosing of CLR 131 in Patients with Relapsed or Refractory Multiple Myeloma Presented at the 61st Annual American Society of Hematology ConferenceFractionated Dosing of CLR 131 in Patients with Relapsed or Refractory Multiple Myeloma Presented at the 61st Annual American Society of Hematology Conference
finance.yahoo.com - December 9 at 12:38 PM
Cellectar Announces Oral Presentation at the 61st Annual American Society of Hematology ConferenceCellectar Announces Oral Presentation at the 61st Annual American Society of Hematology Conference
finance.yahoo.com - December 2 at 9:12 AM
Cellectar Biosciences EPS misses by $0.04Cellectar Biosciences EPS misses by $0.04
seekingalpha.com - November 12 at 9:51 AM
Cellectar Reports Third Quarter 2019 Financial Results and Provides a Corporate UpdateCellectar Reports Third Quarter 2019 Financial Results and Provides a Corporate Update
finance.yahoo.com - November 12 at 9:51 AM
Cellectar Presents a New Phospholipid Drug Conjugate (PDC) at the 2019 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics ConferenceCellectar Presents a New Phospholipid Drug Conjugate (PDC) at the 2019 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference
finance.yahoo.com - October 30 at 12:21 PM
Is Cellectar Biosciences (NASDAQ:CLRB) In A Good Position To Invest In Growth?Is Cellectar Biosciences (NASDAQ:CLRB) In A Good Position To Invest In Growth?
finance.yahoo.com - October 19 at 11:39 AM
Cellectar Announces Poster at the 2019 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference in BostonCellectar Announces Poster at the 2019 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference in Boston
finance.yahoo.com - October 17 at 9:18 AM
Cellectar Presents Poster at the Cancer Research UK-AACR Joint Conference on Engineering and Physical Sciences in OncologyCellectar Presents Poster at the Cancer Research UK-AACR Joint Conference on Engineering and Physical Sciences in Oncology
finance.yahoo.com - October 15 at 9:57 AM
Cellectar Announces Presentation at the Cancer Research UK-AACR Joint Conference on Engineering and Physical Sciences in OncologyCellectar Announces Presentation at the Cancer Research UK-AACR Joint Conference on Engineering and Physical Sciences in Oncology
finance.yahoo.com - October 8 at 12:36 PM
Cellectar Presents Data from DLBCL Cohort of its Phase 2 CLOVER-1 Study at the European Society for Medical Oncology (ESMO) CongressCellectar Presents Data from DLBCL Cohort of its Phase 2 CLOVER-1 Study at the European Society for Medical Oncology (ESMO) Congress
finance.yahoo.com - September 30 at 3:56 PM
Cellectar Receives Orphan Drug Designation from the European Commission for CLR 131 in Multiple MyelomaCellectar Receives Orphan Drug Designation from the European Commission for CLR 131 in Multiple Myeloma
finance.yahoo.com - September 24 at 8:28 AM
Cellectar Biosciences to Present at the Ladenburg Thalmann 2019 Healthcare ConferenceCellectar Biosciences to Present at the Ladenburg Thalmann 2019 Healthcare Conference
finance.yahoo.com - September 19 at 8:59 AM
Cellectar Presents Data from Cohort 6 of its CLR 131 Phase 1 Study in Patients with Relapsed or Refractory Multiple MyelomaCellectar Presents Data from Cohort 6 of its CLR 131 Phase 1 Study in Patients with Relapsed or Refractory Multiple Myeloma
finance.yahoo.com - September 16 at 9:27 AM
Cellectar Announces Oral Presentation at the European Society for Medical Oncology (ESMO) Congress 2019Cellectar Announces Oral Presentation at the European Society for Medical Oncology (ESMO) Congress 2019
finance.yahoo.com - September 10 at 9:08 AM
Cellectar Announces Late-Breaker Poster Presentation at the 17th International Myeloma WorkshopCellectar Announces Late-Breaker Poster Presentation at the 17th International Myeloma Workshop
finance.yahoo.com - September 4 at 11:50 AM
Can We See Significant Institutional Ownership On The Cellectar Biosciences, Inc. (NASDAQ:CLRB) Share Register?Can We See Significant Institutional Ownership On The Cellectar Biosciences, Inc. (NASDAQ:CLRB) Share Register?
finance.yahoo.com - August 20 at 6:38 PM
Cellectar names Dov Elefant as CFOCellectar names Dov Elefant as CFO
seekingalpha.com - August 15 at 6:02 PM
Cellectar Appoints Dov Elefant as Chief Financial OfficerCellectar Appoints Dov Elefant as Chief Financial Officer
finance.yahoo.com - August 15 at 6:02 PM
CLR 131 Advances to Second Malignant Brain Tumor Cohort of Ongoing Pediatric Phase 1 StudyCLR 131 Advances to Second Malignant Brain Tumor Cohort of Ongoing Pediatric Phase 1 Study
finance.yahoo.com - August 14 at 8:39 AM
Cellectar Reports Second Quarter 2019 Financial Results and Provides a Corporate UpdateCellectar Reports Second Quarter 2019 Financial Results and Provides a Corporate Update
finance.yahoo.com - August 12 at 8:44 AM
Cellectars CRL 131 Fast Trackd for DLBCL; shares up 6% premarketCellectar's CRL 131 Fast Track'd for DLBCL; shares up 6% premarket
seekingalpha.com - July 9 at 9:43 AM
Cellectar Receives FDA Fast Track Designation for CLR 131 in Diffuse Large B-Cell LymphomaCellectar Receives FDA Fast Track Designation for CLR 131 in Diffuse Large B-Cell Lymphoma
finance.yahoo.com - July 9 at 9:43 AM
Cellectar up 8% on continued advancement of CLR 131Cellectar up 8% on continued advancement of CLR 131
seekingalpha.com - May 21 at 11:32 AM
Cellectar Expands Third Cohort of its Phase 2 CLOVER-1 Study of CLR 131Cellectar Expands Third Cohort of its Phase 2 CLOVER-1 Study of CLR 131
finance.yahoo.com - May 21 at 11:32 AM
Cellectar Biosciences Announces Closing of $10.0 Million FinancingCellectar Biosciences Announces Closing of $10.0 Million Financing
finance.yahoo.com - May 20 at 5:13 PM
5 Biotech Stocks to Watch in the Second Half of 20195 Biotech Stocks to Watch in the Second Half of 2019
finance.yahoo.com - May 20 at 12:32 PM
Cellectar down 25% on $10M capital raiseCellectar down 25% on $10M capital raise
seekingalpha.com - May 16 at 11:03 AM
Cellectar Biosciences Announces $10.0 Million FinancingCellectar Biosciences Announces $10.0 Million Financing
finance.yahoo.com - May 16 at 11:03 AM
Cellectar up 31% on more positive CLR 131 dataCellectar up 31% on more positive CLR 131 data
seekingalpha.com - May 15 at 6:46 PM
CLR 131 Achieves 50% Overall Response Rate in Cohort 6 of Ongoing Phase 1 Study in Relapsed or Refractory Multiple MyelomaCLR 131 Achieves 50% Overall Response Rate in Cohort 6 of Ongoing Phase 1 Study in Relapsed or Refractory Multiple Myeloma
finance.yahoo.com - May 15 at 9:35 AM
Cellectars CLR 131 Fast Trackd for multiple myeloma; shares up 6%Cellectar's CLR 131 Fast Track'd for multiple myeloma; shares up 6%
seekingalpha.com - May 13 at 6:41 PM
Cellectar Receives FDA Fast Track Designation for CLR 131 in Relapsed or Refractory Multiple MyelomaCellectar Receives FDA Fast Track Designation for CLR 131 in Relapsed or Refractory Multiple Myeloma
finance.yahoo.com - May 13 at 9:35 AM
Cellectar Reports First Quarter 2019 Financial Results and Provides a Corporate UpdateCellectar Reports First Quarter 2019 Financial Results and Provides a Corporate Update
finance.yahoo.com - May 6 at 9:35 AM
Cellectar Biosciences, Inc. (NASDAQ:CLRB): Are Analysts Right About The Drop In Earnings?Cellectar Biosciences, Inc. (NASDAQ:CLRB): Are Analysts Right About The Drop In Earnings?
finance.yahoo.com - April 29 at 5:46 PM
U.S. STOCKS ON THE MOVE-Weed Stocks, Revlon, Shineco - NasdaqU.S. STOCKS ON THE MOVE-Weed Stocks, Revlon, Shineco - Nasdaq
www.nasdaq.com - March 20 at 9:18 AM
Cellectar Biosciences Inc.Cellectar Biosciences Inc.
www.barrons.com - March 19 at 6:26 PM
Cellectar Bio up 40% premarket on advancement of CLR 131Cellectar Bio up 40% premarket on advancement of CLR 131
seekingalpha.com - March 19 at 6:26 PM
This page was last updated on 2/18/2020 by MarketBeat.com Staff

Featured Article: Resistance Level

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel